Moderna Ownership
| MRNA Stock | USD 31.26 0.94 2.92% |
Shares in Circulation | First Issued 2017-03-31 | Previous Quarter 384 M | Current Value 386 M | Avarage Shares Outstanding 353.5 M | Quarterly Volatility 99.5 M |
Moderna Stock Ownership Analysis
About 74.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.2. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Moderna recorded a loss per share of 8.73. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 3rd of August 2017. Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3700 people. To find out more about Moderna contact Stephane Bancel at 617 714 6500 or learn more at https://www.modernatx.com.Besides selling stocks to institutional investors, Moderna also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Moderna's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Moderna's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Moderna Quarterly Liabilities And Stockholders Equity |
|
Moderna Insider Trades History
About 7.0% of Moderna are currently held by insiders. Unlike Moderna's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Moderna's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Moderna's insider trades
Moderna Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Moderna is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Moderna backward and forwards among themselves. Moderna's institutional investor refers to the entity that pools money to purchase Moderna's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Flagship Ventures Management, Inc. | 2025-03-31 | 4.6 M | Two Sigma Investments Llc | 2025-03-31 | 4.5 M | Norges Bank | 2024-12-31 | 3.9 M | Two Sigma Advisers, Llc | 2025-03-31 | 3.8 M | Ubs Asset Mgmt Americas Inc | 2025-03-31 | 3.6 M | Jane Street Group Llc | 2025-03-31 | 3.6 M | Voloridge Investment Management, Llc | 2025-03-31 | 3.3 M | Goldman Sachs Group Inc | 2025-03-31 | 3.2 M | Banque Pictet & Cie Sa | 2025-03-31 | 3.1 M | Vanguard Group Inc | 2025-03-31 | 40.4 M | Blackrock Inc | 2025-03-31 | 27.2 M |
Moderna Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moderna insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moderna's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Moderna insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stephane Bancel over three months ago Acquisition by Stephane Bancel of 357065 shares of Moderna at 30.96 subject to Rule 16b-3 | ||
Hoge Stephen over three months ago Acquisition by Hoge Stephen of 523 shares of Moderna subject to Rule 16b-3 | ||
James Mock over six months ago Disposition of 1453 shares by James Mock of Moderna subject to Rule 16b-3 | ||
Noubar Afeyan over six months ago Disposition of 2100 shares by Noubar Afeyan of Moderna at 121.5699 subject to Rule 16b-3 | ||
Noubar Afeyan over a year ago Disposition of 7996 shares by Noubar Afeyan of Moderna at 122.0689 subject to Rule 16b-3 | ||
James Mock over a year ago Disposition of 705 shares by James Mock of Moderna at 101.9281 subject to Rule 16b-3 |
Moderna's latest congressional trading
Congressional trading in companies like Moderna, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Moderna by those in governmental positions are based on the same information available to the general public.
| 2025-05-08 | Representative Rob Bresnahan | Acquired Under $15K | Verify | ||
| 2025-03-28 | Representative Rob Bresnahan | Acquired Under $15K | Verify |
Moderna Outstanding Bonds
Moderna issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Moderna uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Moderna bonds can be classified according to their maturity, which is the date when Moderna has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Moderna Corporate Filings
F4 | 7th of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 12th of May 2025 Other Reports | ViewVerify | |
8K | 5th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 30th of April 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (8.73) | Revenue Per Share | Quarterly Revenue Growth (0.35) | Return On Assets |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.